Search Results

Your search for Leo I. Gordon, MD, FACP matches 2 pages

Showing 1 - 2

By Leo I. Gordon, MD, FACP / November 10, 2022

‘TRANSFORMING’ Our Thinking About Second-Line Therapy for High-Risk Large B-Cell Lymphoma: Bring in the CARs

As reported in The Lancet by Kamdar et al,1 and summarized in this issue of The ASCO Post, the international phase III TRANSFORM trial was completed in 184 patients with primary refractory or early (≤ 12 months) relapsed large B-cell lymphoma (LBCL). Patients were randomly assigned to receive...

leukemia

By Leo I. Gordon, MD, FACP / July 10, 2017

Idelalisib in Resistant CLL: Benefit Shown, Questions Remain

As reported in The Lancet Oncology by Dr. Andrew Zelenetz and colleagues and reviewed in this issue of The ASCO Post, an international phase III trial in 416 patients with refractory or recurrent chronic lymphocytic leukemia (CLL) addressed the benefit of adding the first-in-class phosphoinositide...

Jul

Today In Oncology

Search Results

Your search for Leo I. Gordon, MD, FACP matches 2 pages

‘TRANSFORMING’ Our Thinking About Second-Line Therapy for High-Risk Large B-Cell Lymphoma: Bring in the CARs

Idelalisib in Resistant CLL: Benefit Shown, Questions Remain

Addition of Glofitamab to R-CHOP or Pola-R-CHP in Younger Patients With High-Risk LBCL

FDA Grants Accelerated Approval to Sunvozertinib for Metastatic NSCLC With EGFR Exon 20 Insertion Mutations

PPP2R1A Mutations Linked to Improved Immunotherapy Outcomes in Ovarian Clear Cell Carcinoma

Bevacizumab Plus Erlotinib in Hereditary and Sporadic Papillary Kidney Cancer

Lean Body Mass–Based Oxaliplatin Dosing and Risk of Neurotoxicity in Adjuvant Treatment of Stage III Colon Cancer